Health Security, Critical Medicines and Biomanufacturing
Medicines, APIs, Diagnostics, Vaccines and Bioindustrial Resilience as Strategic European Assets
What this report establishes
“Health Security, Critical Medicines and Biomanufacturing” is a sourced, structured Defence Finance Monitor analysis, closed on 04 July 2026. It establishes what is at stake, who the actors are and what it means for European defence funding and industry — drawn only from primary and official sources. This page summarises what the 23-page report determines; the figures, the evidence and the conclusions are in the report itself.
Who it's for
Strategy, corporate-development and investment teams that need an ecosystem-level view — budgets, industrial capacity and technology landscapes — before committing capital or capacity.
Key questions this report answers
- Why is Europe's health-security problem now an industrial-capacity question rather than a hospital or reimbursement one?
- What European legal and institutional architecture governs critical medicines and biomanufacturing?
- Which critical value chains, including APIs, antibiotics, vaccines, and diagnostics, show patterns of dependence?
- Which European companies, assets, and programmes reduce that dependence?
Inside this report
- Health security as an industrial question
- The European legal and institutional architecture
- Critical value chains and the pattern of dependence
- European companies, assets and programmes that reduce dependence
Sample page
One full page from the report, exactly as delivered (23 pages in total).
Sources
This report is built only from primary and official sources, cited in the document as of 04 July 2026 — 15 distinct sources including biomerieux.com, competition-policy.ec.europa.eu, corporate.qiagen.com, eca.europa.eu, ecdc.europa.eu, ema.europa.eu, entreprises.gouv.fr, eur-lex.europa.eu, euroapi.com, hadea.ec.europa.eu, health.ec.europa.eu, int.diasorin.com, research-and-innovation.ec.europa.eu, sartorius.com, schott-pharma.com. The source material itself is in the report, not on this page.
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
≈ $349 — charged in euros; indicative equivalent at today's ECB reference rate.
Report — 23 pages · PDF · Analysis as of 04 July 2026 · Licensed single-user copy, watermarked to the buyer
A contents-paged report: a company's structure, portfolio, programme participation and funding record — or a market question measured with a stated method and full bibliography (Eurostat, TED, EU programme data). Use it to check a counterparty or a claim before committing time or budget.
This report €299 · All reports, the Funding Navigator and continuous updates — Annual Professional, €1,500/year excl. VAT →
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
Sold by STRONCATURE S.R.L. (VAT IT05960160652) · Secure checkout by Stripe · Instant watermarked PDF · EU invoice issued after payment.
Prepared by the DFM research desk — editor: Nunzio Mastrolia. Defence Finance Monitor is the defence-finance analysis publication of STRONCATURE S.R.L., Rome.
The analysis is public. The report is the document of record.
The analysis behind this report is published openly on DFM — that is how we work, and it does not change what you are buying. What you buy is the professional edition of that analysis: a dated, complete document with every source cited, structured for desk use, licensed to you, and citable in your own work. The free page is where the analysis lives; the report is what you file, rely on and cite.
What this report covers
Technologies: Military Medical Tech, Synthetic Biology. A sourced, structured 23-page analysis for European defence and dual-use decision-makers, from the DFM research desk and built on official and primary sources.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (04 July 2026). You receive a 23-page report (PDF), watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
Read the free public analysis behind this report · More Strategic reports · Military Medical Tech · Synthetic Biology · All reports
For your role
Investors
Investment intelligence on this company or segment
Request an investment-intelligence brief →SMEs & scale-ups
Position your capability with European programmes
Request a positioning & funding-eligibility check →Universities & research
Technology scouting and multi-seat access for your group
Request technology scouting / team access →Legal & compliance
Eligibility, export-control and regulatory analysis
Request a compliance analysis →Institutional & team access. Labs, primes and universities can equip a whole desk — multi-seat / institutional licensing. Request team / institutional access →
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →